Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    vac069
Previous Study | Return to List | Next Study

VAC069: A Study of Blood-stage Controlled Human P. Vivax Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03797989
Recruitment Status : Recruiting
First Posted : January 9, 2019
Last Update Posted : January 11, 2019
Sponsor:
Information provided by (Responsible Party):
University of Oxford

Brief Summary:

This is a clinical study to assess the safety and feasibility of Plasmodium vivax (P. vivax) blood-stage controlled human malaria infection (CHMI), by inoculation using a newly created source of P. vivax malaria-infected blood.

Six healthy, malaria-naive adult volunteers, ages between 18 and 50 years, will be recruited and undergo three separate P. vivax blood-stage challenges at the CCVTM, Oxford. We will do this by administering a small amount of P. vivax infected blood intravenously on three separate occasions. After the first challenge, the optimal dose for blood-stage CHMI will be selected and used for the second and third challenges.Through each challenge period, volunteers will have blood taken at regular intervals to measure the parasite growth, quantify the sexual parasite forms and assess the immune response to P. vivax infection. In each challenge, following diagnosis, volunteers will be treated with a standard antimalarial course of oral artemether-lumefantrine (Riamet), given over 3 days.

Volunteers who take part in this study will be involved in the trial for approximately 2 years, receiving each of the three challenges at intervals of approximately 5 (and up to 9) months.


Condition or disease Intervention/treatment Phase
Malaria, Vivax Biological: P. vivax infected inoculum (parasitised red blood cells) Early Phase 1

Detailed Description:

This study aims primarily to assess the safety and feasibility of controlled blood-stage human P. vivax malaria infection. This will be the first time that this source of P. vivax infected blood will be utilised and the first P. vivax bloodstage CHMI in Europe. If demonstrated to be safe, it is intended that this parasitised blood bank be used in future CHMI studies to evaluate candidate vaccines.

This study will also assess parasite growth, including quantifying the sexual-stage parasites in the blood, as well as the immune responses in primary, secondary and tertiary P. vivax blood-stage challenge, as further secondary aims. Natural immunity to P. vivax is acquired over time, following repeated exposure. Repeated blood-stage challenge would improve understanding of how the human immune response to P. vivax infected is acquired, and how parasite growth changes in a second or third exposure. Repeated challenges can also be used to test if potential vaccine candidates can protect against repeated malaria infection. If proven to be safe and feasible in this study, this will provide a basis for conducting P. vivax blood-stage re-challenge studies for evaluation of new vaccine candidates.

The study is funded through MultiViVax, a European Commission Horizon 2020 funded project.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 6 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: VAC069: A Clinical Study to Assess the Safety and Feasibility of Controlled Blood-stage Plasmodium Vivax Human Malaria Infection Through Experimental Inoculation of Cryopreserved Infected Erythrocytes in Healthy Malaria-naïve UK Adults
Actual Study Start Date : January 10, 2019
Estimated Primary Completion Date : March 2021
Estimated Study Completion Date : March 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Malaria

Arm Intervention/treatment
Experimental: Group 1
Each volunteer will receive one vial of P. vivax infected inoculum (parasitised red blood cells) at the first blood-stage controlled human malaria infection (CHMI). The optimal dose will be determined following the first CHMI and the selected dose will be administered to all volunteers (Groups 1-3) at both the second and third CHMI.
Biological: P. vivax infected inoculum (parasitised red blood cells)
In the first controlled human malaria infection (CHMI), inoculation of parasitised red blood cells will be at three different doses (1 vial, 1:5 dilution, 1:20 dilution). The optimal inoculation dose will then be selected and administered to all participants in each of the second and third CHMI.

Experimental: Group 2
Each volunteer will receive a fifth of a vial (1:5 dilution) of P. vivax infected inoculum (parasitised red blood cells) at the first blood-stage controlled human malaria infection (CHMI). The optimal dose will be determined following the first CHMI and the selected dose will be administered to all volunteers (Groups 1-3) at both the second and third CHMI.
Biological: P. vivax infected inoculum (parasitised red blood cells)
In the first controlled human malaria infection (CHMI), inoculation of parasitised red blood cells will be at three different doses (1 vial, 1:5 dilution, 1:20 dilution). The optimal inoculation dose will then be selected and administered to all participants in each of the second and third CHMI.

Experimental: Group 3
Each volunteer will receive one twentieth of a vial (1:20 dilution) of P. vivax infected inoculum (parasitised red blood cells) at the first blood-stage controlled human malaria infection (CHMI). The optimal dose will be determined following the first CHMI and the selected dose will be administered to all volunteers (Groups 1-3) at both the second and third CHMI.
Biological: P. vivax infected inoculum (parasitised red blood cells)
In the first controlled human malaria infection (CHMI), inoculation of parasitised red blood cells will be at three different doses (1 vial, 1:5 dilution, 1:20 dilution). The optimal inoculation dose will then be selected and administered to all participants in each of the second and third CHMI.




Primary Outcome Measures :
  1. Safety of primary P. vivax blood-stage CHMI as measured by (S)AE occurrences [ Time Frame: 3 months ]
  2. The optimal inoculation dose to take forward to future P. vivax CHMI studies [ Time Frame: 3 months ]

    Choosing the optimal inoculation dose to take forward to future P. vivax CHMI studies will be decided based on the following algorithm:

    Ideal choice = the first group (2/2 volunteers) to reach diagnosis criteria (within 21 days). N.B. If both volunteers in Group 1 develop infection AND both volunteers in Group 2 (or 3) reliably develop infection within 5 days of Group 1 (and within the 21-day window) then the lowest dose group should be chosen.


  3. Feasibility of primary P. vivax blood-stage CHMI as measured by successful infection (development of detectable persistent parasitaemia by thick film and qPCR +/- clinical symptoms) [ Time Frame: 3 months ]

Secondary Outcome Measures :
  1. Safety of secondary and tertiary P. vivax controlled blood-stage CHMI as measured by (S)AE occurrences [ Time Frame: 12 months ]
  2. Immune response to primary, secondary and tertiary P. vivax pre-treatment [ Time Frame: 12 months ]
    As measured by antibody, B cell and T cell responses through experimental injection of P. vivax infected erythrocytes

  3. Gametocytaemia [ Time Frame: 12 months ]
    As measured by qPCR in primary, secondary and tertiary P. vivax blood-stage CHMI.

  4. Feasibility of secondary and tertiary P. vivax controlled blood-stage CHMI as measured by successful infection (development of detectable persistent parasitaemia by thick film and qPCR +/- clinical symptoms) [ Time Frame: 12 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy adult aged 18 to 50 years.
  • Red blood cells positive for the Duffy antigen/chemokine receptor (DARC).
  • Normal serum levels of Glucose-6-phosphate dehydrogenase (G6PDH).
  • Negative haemoglobinopathy screen
  • Able and willing (in the Investigator's opinion) to comply with all study requirements.
  • Willing to allow the Investigators to discuss the volunteer's medical history with their General Practitioner.
  • Women only: Must practice continuous effective contraception for the duration of the clinic visits (first 3 months post-CHMI).
  • Agreement to permanently refrain from blood donation
  • Written informed consent to participate in the trial.
  • Reachable (24/7) by mobile phone during the period between CHMI and completion of all antimalarial treatment.
  • Willing to take a curative anti-malarial regimen following CHMI.
  • Willing to reside in Oxford for the duration of the study, until antimalarials have been completed.
  • Answer all questions on the informed consent quiz correctly.

Exclusion Criteria:

  • History of clinical malaria (any species).
  • Travel to a clearly malaria endemic locality during the study period or within the preceding six months.
  • Use of systemic antibiotics with known antimalarial activity within 30 days of CHMI (e.g. trimethoprimsulfamethoxazole, doxycycline, tetracycline, clindamycin, erythromycin, fluoroquinolones and azithromycin).
  • Red blood cells negative for the Duffy antigen/chemokine receptor (DARC).
  • Glucose-6-phosphate dehydrogenase (G6PDH) deficient.
  • Current anaemia (haemoglobin <120 g/L for a female volunteer or <130 g/L for a male volunteer) prior to primary CHMI. (However, for enrolment into secondary and tertiary CHMIs slightly lower haemoglobin values (≤0.5 g/L) will be permitted at the discretion of the Investigator, to account for the blood volume donated during the previous CHMI).
  • Use of immunoglobulins or blood products (e.g., blood transfusion) at any time in the past.
  • Peripheral venous access unlikely to allow twice daily blood testing (as determined by the Investigator).
  • Receipt of an investigational product in the 30 days preceding enrolment, or planned receipt during the study period.
  • Prior receipt of an investigational vaccine likely to impact on interpretation of the trial data or the P. vivax parasite as assessed by the Investigator.
  • Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed).
  • History of allergic disease or reactions likely to be exacerbated by malaria infection.
  • Pregnancy, lactation or intention to become pregnant during the study.
  • Use of medications known to cause prolongation of the QT interval and existing contraindication to the use of Malarone.
  • Use of medications known to have a potentially clinically significant interaction with Riamet and Malarone.
  • Any clinical condition known to prolong the QT interval.
  • History of cardiac arrhythmia, including clinically relevant bradycardia.
  • Disturbances of electrolyte balance, e.g. hypokalaemia or hypomagnesaemia.
  • Family history of congenital QT prolongation or sudden death.
  • Contraindications to the use of both of the proposed anti-malarial medications; Riamet Malarone.
  • History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ).
  • History of serious psychiatric condition that may affect participation in the study.
  • Any other serious chronic illness requiring hospital specialist supervision. Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 25 standard UK units every week.
  • Suspected or known injecting drug abuse in the 5 years preceding enrolment.
  • Hepatitis B surface antigen (HBsAg) detected in serum.
  • Seropositive for hepatitis C virus (antibodies to HCV) at screening or at C-7 (unless has taken part in a prior hepatitis C vaccine study with confirmed negative HCV antibodies prior to participation in that study, and negative HCV RNA PCR at screening for this study).
  • Positive family history in both 1st AND 2nd degree relatives < 50 years old for cardiac disease.
  • Volunteers unable to be closely followed for social, geographic or psychological reasons.
  • Any clinically significant abnormal finding on biochemistry or haematology blood tests, urinalysis or clinical examination. In the event of abnormal test results, confirmatory repeat tests will be requested. Procedures for identifying laboratory values meeting exclusion criteria are shown in Appendix A.
  • Any other significant disease, disorder, or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03797989


Contacts
Layout table for location contacts
Contact: Volunteer Recruitment Co-ordinator Volunteer Recruitment Co-ordinator 01865 611424 vaccinetrials@ndm.ox.ac.uk
Contact: Volunteer Recruitment Co-ordinator vaccinetrials@ndm.ox.ac.uk

Locations
Layout table for location information
United Kingdom
Centre for Clinical Vaccinology & Tropical Medicine Recruiting
Oxford, Oxfordshire, United Kingdom, OX3 7LE
Contact: Angela M Minassian    01865 611425    angela.minassian@ndm.ox.ac.uk   
Contact: Fay L Nugent    01865 611412    fay.nugent@ndm.ox.ac.uk   
Sponsors and Collaborators
University of Oxford
Investigators
Layout table for investigator information
Principal Investigator: Angela M Minassian, MBBS MA DPhil MRCP FRCPath University of Oxford

Layout table for additonal information
Responsible Party: University of Oxford
ClinicalTrials.gov Identifier: NCT03797989     History of Changes
Other Study ID Numbers: VAC069
First Posted: January 9, 2019    Key Record Dates
Last Update Posted: January 11, 2019
Last Verified: January 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Malaria
Malaria, Vivax
Protozoan Infections
Parasitic Diseases
Vaccines
Immunologic Factors
Physiological Effects of Drugs